-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, MwJd2UlEO+hDw1xRT1GQMlXzJfaqPKtrMik/KND+2ORXSceGdPA8McRUjMNKKuAb tWwXuXpGPAEESam0SNde8Q== 0000891092-04-003851.txt : 20040804 0000891092-04-003851.hdr.sgml : 20040804 20040803174337 ACCESSION NUMBER: 0000891092-04-003851 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20040803 ITEM INFORMATION: Financial statements and exhibits ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20040804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PHOTOMEDEX INC CENTRAL INDEX KEY: 0000711665 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 592858100 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-11635 FILM NUMBER: 04949536 BUSINESS ADDRESS: STREET 1: 147 KEYSTONE DRIVE CITY: MONTGOMERYVILLE STATE: PA ZIP: 18936 BUSINESS PHONE: 2156193600 MAIL ADDRESS: STREET 1: 147 KEYSTONE DRIVE CITY: MONTGOMERYVILLE STATE: PA ZIP: 18936 FORMER COMPANY: FORMER CONFORMED NAME: LASER PHOTONICS INC DATE OF NAME CHANGE: 19920703 8-K 1 e18701_8k.txt FORM 8-K ================================================================================ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) August 3, 2004 PhotoMedex, Inc. - -------------------------------------------------------------------------------- (Exact name of registrant as specified in its charter) Delaware 0-11635 59-2858100 - ---------------------------- ---------------- ------------------- (State or other jurisdiction (Commission File (IRS Employer of incorporation) Number) Identification No.) 147 Keystone Drive, Montgomeryville, Pennsylvania 18936 - ------------------------------------------------- ------------------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code 215.619.3600 - -------------------------------------------------------------------------------- (Former name or former address if changed since last report) ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS. (C) EXHIBITS. 99.1 Press Release, dated August 3, 2004. ITEM 9. Regulation FD Disclosure. (Information furnished pursuant to Item 12, Results of Operations and Financial Condition.) On August 3, 2004, the Registrant reported its results of operations for its second quarter ended June 30, 2004. A copy of the press release issued by the Registrant concerning the foregoing results is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information contained here and in the accompanying exhibit is being furnished pursuant to "Item 12. Results of Operations and Financial Condition" in accordance with interim guidance issued by the Securities and Exchange Commission in Release No. 33-8216. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing. The information in this report, including the exhibit hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended or be otherwise subject to the liabilities of that section or Sections 11 and 12 (a) (2) of the Securities Act of 1933, as amended. We included in our press release certain historical non-GAAP financial measures with respect to the three-month periods ended June 30, 2004 and June 30, 2003, as defined in Regulation G promulgated by the Securities and Exchange Commission. We believe that the presentation of historical non-GAAP financial measures provides useful supplementary information to investors. These historical non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PhotoMedex, Inc. Date: August 3, 2004 By: /s/ Dennis M. McGrath ----------------------------- Dennis M. McGrath Chief Financial Officer 3 EXHIBIT INDEX Exhibit No. Description 99.1 Press release of PhotoMedex, Inc., dated August 3, 2004, regarding the announcement of the Company's second quarter of 2004 earnings. 4 EX-99.1 2 e18701ex99_1.txt PRESS RELEASE Exhibit 99.1 PhotoMedex Announces Second Quarter 2004 Results MONTGOMERYVILLE, Pa., Aug. 3 /PRNewswire-FirstCall/ -- PhotoMedex, Inc. (Nasdaq: PHMD) today announced the results of its operations for the quarter ended June 30, 2004. Revenues for the second quarter ended June 30, 2004 were $4,323,134, an increase of 12.5% over the same period last year and 7.4% increase over the first quarter of 2004. The net loss for the quarter ended June 30, 2004 was $1,207,167, or $0.03 per diluted share. The net loss for the quarter ended June 30, 2003 was $1,686,102, or $0.05 per diluted share. The revenue and net loss for the six months ended June 30, 2004 were $8,348,364 and $2,570,249, respectively, or $0.07 per diluted share. The revenue and net loss for the six months ended June 30, 2003 were $7,316,176 and $3,360,430, respectively, or $0.10 per diluted share. As of June 30, 2004, the Company had cash and cash equivalents of $5,687,975, a decrease of $137,981 from March 31, 2004. Jeffrey O'Donnell, PhotoMedex CEO and President, commented, "We are pleased with the results of our core business segments, as well as with the recent medical policy approvals put in place for our XTRAC(R) laser therapy system by some of the nation's leading health insurers. Our team has accomplished a great deal over this past quarter in terms of expanding the size of our addressable markets and creating a more attractive product offering in those markets. We are now focused on pure execution and positioning ourselves to build on those successes. We look forward to today's conference call and the opportunity to review with our shareholders our increased revenues, improved margins and the impact of reimbursement on our business." The following were among the more notable recent achievements: Reimbursement: * WellPoint Blue Cross and Blue Shield Plans, the nation's 2nd largest health plan with 15 million medical members, adopts XTRAC(R) reimbursement * Aetna, with 13.6 million medical members, adopts XTRAC(R) reimbursement * The Regence Group, with 3 million medical members, adopts XTRAC(R) reimbursement Financial: * Domestic XTRAC(R) yields 21.6% growth over first quarter 2004 * Surgical Services yields 18.0% growth over first quarter 2004 * GE Capital makes available $2.5 million lease line of credit * Stock warrants exercised, amounting to $904,886 incremental cash New Product Development: * FDA market clearance and CE mark obtained for the manufacture and distribution of a CO2 surgical laser which will lower the cost of delivery for the Surgical Services group * FDA market clearance and CE mark obtained for the manufacture and distribution of a Diode laser indicated for use in General Surgery, Neurosurgery, ENT, GYN, and LEG VEIN Procedures. Our previously FDA cleared Venous Fiber can be used with our Diode Laser. Business Development: * Entered into a Product Development agreement with AzurTec, Inc. for the design of a cancer detection device and process to be marketed to MOHS Surgeons in Dermatology Corporate Governance: * Appointment of David W. Anderson to the board of directors Additional notable activities and Company recognition during and following the second quarter included: * Jeffrey O'Donnell, CEO was a speaker and panelist on insurance reimbursement issues at the recent 2004 Healthcare CEO Summit, held in Pebble Beach, California * The Archives of Dermatology published a study on using the XTRAC(R) to effectively treat the symptoms of Oral Lichen Planus, a notoriously difficult-to-control disease of the mouth * Jeffrey O'Donnell, CEO was named a finalist for the Ernst & Young Entrepreneur of the Year Award * The Company participated at the 2004 American Academy of Dermatology Summer Meeting held in New York City, July 28 through August 1, 2004 PhotoMedex will hold a conference call to discuss the Company's second quarter 2004 results on Tuesday, August 3, 2004 at 4:30 p.m. Eastern Time. To participate in the conference call, dial 1.800.946.0786 (and confirmation code # 886607) approximately 5 to 10 minutes prior to the scheduled start time. If you are unable to participate, a digital replay of the call will be available from Tuesday, August 3, from 7:30 p.m. ET until midnight on Tuesday, August 17, by dialing 1.888.203.1112 and using confirmation code #886607. The live broadcast of PhotoMedex, Inc.'s quarterly conference call will be available online by going to www.photomedex.com and clicking on the link to Investor Relations, and at www.streetevents.com. The online replay will be available shortly after the call at those sites. About PhotoMedex: PhotoMedex provides contract medical procedures to hospitals, surgi- centers and doctors' offices, offering a wide range of products and services across multiple specialty areas, including dermatology, urology, gynecology, orthopedics, and other surgical specialties. The company is a leader in the development, manufacturing and marketing of medical laser products and services. Some portions of the conference call, particularly those describing PhotoMedex' strategies, operating expense reductions and business plans, will contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1993, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While PhotoMedex is working to achieve those goals, actual results could differ materially from those projected in the forward- looking statements as a result of a number of factors, including difficulties in marketing its products and services, need for capital, competition from other companies and other factors, any of which could have an adverse effect on the business plans of PhotoMedex, its reputation in the industry or its results. In light of significant uncertainties inherent in forward-looking statements included herein and in the conference call, the inclusion of such information in the conference call should not be regarded as a representation by PhotoMedex or its subsidiaries that the forward-looking statements will be achieved. For further information, please contact: Investors, Matt Clawson of Allen & Caron, +1-949-474-4300, matt@allencaron.com, for PhotoMedex, Inc.; or Dennis McGrath, CFO of PhotoMedex, Inc., +1-215-619-3287, info@photomedex.com. PHOTOMEDEX, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Three Months Ended June 30, Six Months Ended June 30, 2004 2003 2004 2003 Revenues $4,323,134 $3,842,699 $8,348,364 $7,316,176 Cost of Sales 2,631,369 2,666,232 5,125,435 5,076,490 Gross profit 1,691,765 1,176,467 3,222,929 2,239,686 Operating expenses: Selling, general and administrative 2,406,453 2,387,020 4,876,877 4,681,612 Research and development and engineering 481,243 465,134 897,193 877,066 2,887,696 2,852,154 5,774,070 5,558,678 Loss from operations before interest expense, net (1,195,931) (1,675,687) (2,551,141) (3,318,992) Interest expense, net 11,236 10,415 19,108 41,438 Net loss $(1,207,167) $(1,686,102) $(2,570,249) $(3,360,430) Basic and diluted net loss per share $(0.03) $(0.05) $(0.07) $(0.10) Shares used in computing basic and diluted net loss per share 38,546,338 33,644,326 38,159,819 32,547,784 PHOTOMEDEX, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) June 30, 2004 December 31, 2003 Assets Cash and cash equivalents $5,687,975 $6,633,468 Accounts receivable, net 3,617,921 3,483,030 Inventories 4,141,828 4,522,462 Other current assets 791,546 334,002 Property and equipment, net 4,521,194 4,005,205 Other assets 3,861,673 3,774,564 Total Assets $22,622,137 $22,752,731 Liabilities and Stockholders' Equity Accounts payable and accrued liabilities $3,211,233 $3,445,559 Other current liabilities 1,548,408 1,501,034 Bank and lease notes payable 2,549,202 1,828,063 Stockholders' equity 15,313,294 15,978,075 Total Liabilities and Stockholders' Equity $22,622,137 $22,752,731 SOURCE PhotoMedex, Inc. -0- 08/03/2004 /CONTACT: investors, Matt Clawson of Allen & Caron, +1-949-474-4300, matt@allencaron.com, for PhotoMedex, Inc.; or Dennis McGrath, CFO of PhotoMedex, Inc., +1-215-619-3287, info@photomedex.com/ /Web site: http://www.streetevents.com / /Web site: http://www.photomedex.com / (PHMD) CO: PhotoMedex, Inc. ST: Pennsylvania, California IN: MTC BIO HEA INS SU: ERN CCA -----END PRIVACY-ENHANCED MESSAGE-----